Education
About Us
Working with TipRanks
Follow Us
Bio-Techne (TECH)
NASDAQ:TECH
TECH Stock Chart & Stats
$58.51
-$0.13(-0.17%)
At close: 4:00 PM EST
$58.51
-$0.13(-0.17%)
Day’s Range― - ―
52-Week Range$46.01 - $79.28
Previous CloseN/A
Volume102.39K
Average Volume (3M)1.94M
Market Cap
$9.12B
Enterprise Value$8.95B
Total Cash (Recent Filing)$144.96M
Total Debt (Recent Filing)$394.47M
Price to Earnings (P/E)119.6
Beta1.00
Next Earnings
Feb 03, 2026EPS Estimate
0.43Next Dividend Ex-DateN/A
Dividend Yield0.55%
Share Statistics
EPS (TTM)0.42
Shares Outstanding155,812,700
10 Day Avg. Volume1,807,502
30 Day Avg. Volume1,936,340
Financial Highlights & Ratios
PEG Ratio-1.97
Price to Book (P/B)4.22
Price to Sales (P/S)6.64
P/FCF Ratio31.59
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue7.35
Enterprise Value/Gross Profit11.22
Enterprise Value/Ebitda39.91
Forecast
1Y Price Target
$67.38Price Target Upside15.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)1.98
Revenue Forecast (FY)$1.22B
Bulls Say, Bears Say
Bulls Say
End Market MomentumThe underlying end market drivers are showing positive underlying momentum, contributing positively to stock movement.
Management ConfidenceManagement is confident that the growth outlook remains achievable with expected margin expansion.
Pharma And Biotech GrowthPharma showing momentum and biotech funding greenshoots are key for the stock to move higher.
Bears Say
Order Timing HeadwindsManagement highlighted order timing headwinds within its GMP proteins business as a key driver behind the top-line miss.
Timing IssuesTiming issues were the main culprit of the organic miss and lower organic guide.
Top-line MissTechne’s third-quarter print came in below expectations on the top line with weaker Protein Sciences driving the miss.
Bio-Techne News
TECH FAQ
What was Bio-Techne’s price range in the past 12 months?
Bio-Techne lowest stock price was $46.01 and its highest was $79.28 in the past 12 months.
What is Bio-Techne’s market cap?
Bio-Techne’s market cap is $9.12B.
When is Bio-Techne’s upcoming earnings report date?
Bio-Techne’s upcoming earnings report date is Feb 03, 2026 which is in 49 days.
How were Bio-Techne’s earnings last quarter?
Bio-Techne released its earnings results on Nov 05, 2025. The company reported $0.42 earnings per share for the quarter, missing the consensus estimate of $0.421 by -$0.001.
Is Bio-Techne overvalued?
According to Wall Street analysts Bio-Techne’s price is currently Undervalued.
Does Bio-Techne pay dividends?
Bio-Techne pays a Quarterly dividend of $0.08 which represents an annual dividend yield of 0.55%. See more information on Bio-Techne dividends here
What is Bio-Techne’s EPS estimate?
Bio-Techne’s EPS estimate is 0.43.
How many shares outstanding does Bio-Techne have?
Bio-Techne has 155,812,700 shares outstanding.
What happened to Bio-Techne’s price movement after its last earnings report?
Bio-Techne reported an EPS of $0.42 in its last earnings report, missing expectations of $0.421. Following the earnings report the stock price went down -1.899%.
Which hedge fund is a major shareholder of Bio-Techne?
Currently, no hedge funds are holding shares in TECH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bio-Techne Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$67.38 (15.16% Upside)
$67.38 (15.16% Upside)
Blogger Sentiment
Bullish
TECH Sentiment 80%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 3.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.1%
Last 30 Days ▼ 4.2%
Last 30 Days ▼ 4.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-23.36%
12-Months-Change
Fundamentals
Return on Equity
3.80%
Trailing 12-Months
Asset Growth
-7.67%
Trailing 12-Months
Company Description
Bio-Techne
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
TECH Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a mixed performance for Bio-Techne. While there are significant challenges in biotech funding and revenue declines in specific segments, there are positive developments in large pharma growth, geographic expansion in China, and margin improvements. The company also made notable progress in sustainability and some product lines, but faces hurdles in cell therapy and biotech funding.View all TECH earnings summariesTECH Net revenue Breakdown
71.35% Protein Sciences
28.39% Diagnostics and Genomics
-0.08% Intersegment
0.34% Other revenue
TECH Stock 12 Month Forecast
Average Price Target
$67.38
▲(15.16% Upside)
Technical Analysis
Corcept Therapeutics
―
Halozyme
―
Jazz Pharmaceuticals
―
Rhythm Pharmaceuticals
―
Roivant Sciences
―
Ownership Overview
0.28% Insiders
39.13% Mutual Funds
32.59% Other Institutional Investors
3.53% Public Companies and
Individual Investors